

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: divisional

Filed: tba

1st Inventor: OGI, Kazuhiro

For: Novel Human Ependymin-like Protein

Atty. Dkt. No. 2417 USIP

Art Unit: 1647

Examiner: R. Hayes

Allowed:

Batch:

Paper No.:

Information Disclosure Statement

MAIL STOP NEW APPLICATION

Commissioner for Patents

P.O. Box 1450

Arlington, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached form PTO-1449. A legible copy of each listed reference

() are enclosed.

(X) has been previously submitted, and/or made of record in prior patent application Serial No. 09/242,890.

This information disclosure statement is being submitted

(X) within 3 months of the filing date of the above-identified application

(X) before the mailing date of the first Office Action on the merits,

(X) thus, no certification or fee is required.

(X) The Commissioner is authorized to charge any required fee or to credit any overpayment to USPTO Deposit Account 500799.

For each non-English language reference listed on the attached Form PTO-1449, reference is made to the concise explanation attached thereto.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached Form PTO-1449 be returned in accordance with MPEP §9609.


Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully invited to call applicants' attorney.

Respectfully submitted,

Dated: July 2, 2003

(847)383-3372

(847)383-3391



Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA

Page 1 of 1		FORM PTO 1449 (modified)		ATTY DOCKET NO.: 2417US1P		SERIAL NO.: tba	
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)							
Date Submitted to PTO:				APPLICANT: OGI, Kazuhiro et al.			
				FILING DATE: tba		GROUP: 1647	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	REF No.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL	REF No.	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	A1	WO 92/20362 A	11/26/1992	WIPO			
OTHER DOCUMENT(S)							
*EXAMINER INITIAL	REF No.	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.					
	A2	Schmidt, R. et al. "Immunological cross-reactivity of cultured rat hippocampal neurons..." Brain Research, 386, 1986; pp 245-257					
	A3	Muller-Schmid, A. et al. "Molecular analysis of ependymins..." J. Mol. Evol., 36, 1993; pp 578-585					
	A4	Hoffmann, W. & Schwartz, H., "Ependymins: Meningeal-derived extracellular matrix proteins at the blood-brain barrier" Int. Rev. Cytol. 165, 1966; pp. 121-158					
	A5	Muller-Schmid, A. et al. "Ependymins from the cerebrospinal fluid of salmoid fish..." Gene, 118, 1992; pp 189-196					
	A6	Orti, G. & Meyer, A. "Molecular evolution of Ependymin and the phylogenetic resolution of early divergences among Euteleost fishes" Mol. Biol. Evol., 13(4), 1996; pp 556-573					
	A7	Adams, D. et al. "Genes Encoding Giant Danio and Golden Shiner Ependymin" Neurochemical Research, 21(3), 1996; pp 377-384					
	A8	Rudinger, J. "Characteristics of amino acids as components of peptide hormone sequence" in Peptide Hormones (ed. J. Parsons) University Park Press, Baltimore; 1976; pp 1-7					
	A9	Shashoua VE. et al. "Dibutylrlyl Cyclic AMP stimulates expression of Ependymin mRNA and the Synthesis and release of the protein into the culture medium by Neuroblastoma cells" J. Neurosci. Research 32, 1992; pp 239-244					
EXAMINER:				DATE CONSIDERED:			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.